Loss of Heterozygosity at 1p, 7q, 17p, and 22q in Meningiomas

In Bok Chang, M.D., Ph.D.,1 Byung Moon Cho, M.D., Ph.D.,1 Seung Myung Moon, M.D., Ph.D.,1 Se Hyuck Park, M.D., Ph.D.,1 Sae Moon Oh, M.D., Ph.D.,1 Seong Jin Cho, M.D., Ph.D.2

Departments of Neurosurgery,1 Pathology,2 Hallym University College of Medicine, Seoul, Korea

Objective: Allelic losses or loss of heterozygosity (LOH) at many chromosomal loci have been found in the cells of meningiomas. The objective of this study was to evaluate LOH at several loci of different chromosomes (1p32, 17p13, 7q21, 7q31, and 22q13) in different grades of meningiomas.

Methods: Forty surgical specimens were obtained and classified as benign, atypical, and anaplastic meningiomas. After DNA extraction, ten polymorphic microsatellite markers were used to detect LOH. Medical and surgical records, as well as pathologic findings, were reviewed retrospectively.

Results: LOH at 1p32 was detected in 24%, 60%, and 60% in benign, atypical, and anaplastic meningiomas, respectively. Whereas LOH at 7q21 was found in only one atypical meningioma. LOH at 7q31 was found in one benign meningioma and one atypical meningioma. LOH at 17p13 was detected in 4%, 40%, and 80% in benign, atypical, and anaplastic meningiomas, respectively. LOH at 22q13 was seen in 48%, 60%, and 60% in benign, atypical, and anaplastic meningiomas, respectively. LOH results at 1p32 and 17p13 showed statistically significant differences between benign and non-benign meningiomas.

Conclusion: LOH at 1p32 and 17p13 showed a strong correlation with tumor progression. On the other hand, LOH at 7q21 and 7q31 may not contribute to the development of the meningiomas.

KEY WORDS: Chromosome · Loss of heterozygosity · Meningiomas.
DNA extraction

All specimens were fixed in 10% formaldehyde and paraffin-embedded slices were obtained. Forty paraffin-embedded tumors were examined. Serial sections of 5 µm thickness containing tumor and non-tumor portions (normal tissue of meninges) were performed on each surgical specimen. After staining with H&E, the sections were microdissected to obtain an extract of deoxyribonucleic acid (DNA). Microdissected tissues were then deparaffinized in xylene for 2 hours. To extract DNA from specimens, the selected tissues were placed in 1.5 mL of digestion buffer (100 mM Tris-HCl, pH 8.0; 1% Tween 20, and 0.1 mg/mL proteinase K) at 52°C for two days. After digestion, proteinase K was inactivated by incubation at 96°C for 10 min and the samples were centrifuged at 14,000 rpm for 30 min. The extracts (about 2 µL) were used as template DNA for polymerase chain reaction (PCR).

LOH analysis and decision

A total of ten polymorphic microsatellite markers were used: D1S193 and D1S463 for chromosome 1p32, D7S660 and D7S492 for 7q21, D7S486 and D7S655 for 7q31, D17S796 and TP53 for 17p13, and D22S193 and D22S929 for 22q13. Commercially available primers for these markers were used (GIBCO Inc., Carlsbad, CA, USA). The genomic sequences of the primers are listed in Table 1. PCR was carried out in a thermal cycler (Perkin Elmer Cetus 9700, USA). PCR amplifications were performed using 2 µL of DNA template, 0.25 µL of each primer, 1.25 mM NTP with 1/2dCTP, 1.5 mM MgCl₂, 0.6 U Taq polymerase (0.07 µL), and 10 x PCR buffer. Every cycle consisted of denaturation at 94°C for 30 seconds, annealing at 55-60°C for 30s, and extension at 72°C for 40s, followed by a final extension at 72°C for 10 min. Amplified PCR products (3 µL) were analyzed by 12% polyacrylamide gel electrophoresis. Using silver staining, the gain or loss of heterozygosity was assessed. The band intensity of two alleles in each case was determined by densitometric analysis (Pharmacia, San Francisco, CA, USA).

LOH was assigned if there was a decrease in signal intensity greater than 50% in the tumor tissue allele. In this study, LOH: loss of heterozygosity

| Chromosome | Microsatellite markers | Genomic sequences |
|------------|-----------------------|------------------|
| 1p32       | D1S193                | 5'-ACCTCAGGCTCGGAGCAGG-3' |
|            | D1S463                | 5'-AGACTGGGAAAAATGCAATGG-3' |
| 7q21       | D7S660                | 5'-TAGCCCAACCTGCGG-3' |
|            | D7S492                | 5'-AGCTTGATAGTGGAATACTTG-3' |
| 7q31       | D7S486                | 5'-AAAGGCGAATGTATAATCCC-3' |
|            | D7S655                | 5'-GCCCAGGTTATGATGATG-3' |
| 17p13      | TP53                  | 5'-CAGTAATCTGGTCCTGAGGAC-3' |
|            | D17S796               | 5'-AAATACCGACCAAAATGGTTC-3' |
| 22q13      | D22S193               | 5'-ACGGTCAGCTAAAATCCAC-3' |
|            | D22S929               | 5'-ACCTCGAGATCAACACTCTCCCT-3' |

LOH in Meningiomas | IB Chang, et al.

RESULTS

Of 40 patients, there were 27 females and 13 males and the...
mean age was 44 years with a range of 27-67. Twenty-five benign, 10 atypical, and 5 anaplastic meningiomas were identified. The locations of tumors were 22 in the convexity, 7 in the parasagittal area, 6 in the falx, 3 in the lateral ventricle, and 2 in the sphenoidal ridge. Histological subtypes of 25 benign meningiomas consisted of 17 meningotheliomatous, 4 transitional, 3 fibrous, and 1 psammomatous type. The clinical and experimental data were described in Table 2.

**Frequency of LOH according to the grades**

LOH at loci 1p32, 7q21, 7q31, 17p13 and 22q13 was detected in 15 (37.5%), 1 (2.5%), 2 (5%), 9 (22%), and 21 (52.5%) cases of meningiomas, respectively (Table 3). Identification of LOH at 1p32 was made in 24% of benign, 60% of atypical and 60% of anaplastic meningiomas, respectively. The authors classified grades as benign and non-benign (atypical or anaplastic) to assess statistical signifi-
cance, and there was a significant relationship between benign and non-benign meningiomas and LOH at 1p32 ($p = 0.0228$) (Fig. 1). Whereas LOH at 7q21 was found in only one atypical meningioma, LOH at 7q31 was seen in one benign meningioma and one atypical meningioma. No significant correlations were identified between benign and non-benign meningiomas at 7q21 and 7q31. LOH on 17p13 was detected in 4%, 40%, and 80% of benign, atypical, and anaplastic meningiomas, respectively (Fig. 1). LOH on 22q13 was detected in 48%, 60%, and 60% of benign, atypical, and anaplastic meningiomas, respectively. LOH results at 17p13 showed a statistically significant difference between benign and non-benign meningiomas ($p = 0.0006$). However, there was no significance at 22q13 ($p = 0.461$).

**Frequency of LOH according to the histological subtypes**

Of 25 benign meningiomas, excluding 10 atypical and 5 anaplastic meningiomas, identification of LOH at 1p32, according to histological subtypes, was seen 4 (23.5%) in meningothelial, 1 (33.3%) fibrous, and 1 (25%) in transitional type. In the case of 7q31 and 17p13, LOH was detected 1 (5.3%) in meningothelial type, respectively. Eight cases (47%) of meningothelial and 3 cases (75%) of transitional meningiomas showed LOH at 22q13 ($p = 0.399$). There were no statistical correlations between subtypes and LOH in any of the chromosomal regions examined in this study.

**DISCUSSION**

Since the identification of monosomy of chromosome 22, the molecular studies of meningiomas and gliomas have advanced in accordance with various cytogenetic developments. LOH examined in this study led to the discovery of a tumor suppressor gene. The analysis of LOH using microsatellite probes has been reported in many tumors, especially malignant tumors. In meningiomas, many authors have revealed deletions in various chromosomes using LOH analysis. Of them, the most common site of LOH was chromosome 22, followed by chromosome 1p.

The characteristic findings of this study were: 1) the detection of LOH was higher at 1p and 22q (24% and 48%, respectively) than that of at 7q21, 7q31 and 17p3 (0%, 4%, and 4%, respectively) in benign meningiomas, 2) LOH was most frequently detected at 22q13 and there was a significant difference of LOH between benign and non-benign meningiomas at 1p32 and 17p13.

Neurofibromatosis type 2 (NF 2) is a tumor suppressor gene on chromosome 22q, which has been implicated in the development of benign meningiomas. NF2 gene mutations occur with a similar frequency between benign and non-benign (atypical or anaplastic) meningiomas, which suggests that NF2 is associated with meningioma initiation rather than progression. According to Weber et al., the initial event of meningioma formation was related to an allelic loss at 22q. LOH at 1p, 6q, 10, 14q, and 18q, and gains in 1q, 9q, 12q, 15q, 17q, and 20q were associated with atypical meningiomas. As reported by Kim et al., LOH at 22q was seen in 47% of benign and in 100% of anaplastic meningiomas and there was a statistically significant correlation between the two groups. In addition, Lee et al. reported that 12.5-64% of benign meningiomas showed...
LOH of 22q and anaplastic meningiomas demonstrated 100% LOH on chromosome 22. In our study, LOH at 22q13 of benign meningiomas was 48%, which was similar to the results of other studies. In anaplastic meningiomas, however, LOH at 22q was 60%, and there was no significant correlation between two groups. This finding implies that LOH at 22q is related to tumorigenesis more than than tumor progression.

LOH at 1p is the second most frequent chromosomal abnormality in meningiomas and has been shown to be associated with meningioma progression. The detection rate of LOH in 1p is 21-33% in benign and 71-85% in anaplastic meningiomas. Leuraud et al. stated that LOH at 1p occurs after the loss of chromosome 22 and is more frequent in grade 2 than grade 1 meningiomas. In our study, LOH at 1p occurred more frequently in non-benign than in benign meningiomas, and in the transitional type more than in the meningothelial type. There was a significant correlation in grades, but no statistical association in histological subtypes (p = 0.02 and p = 0.18, respectively).

P53 gene located on chromosome 17p is a tumor suppressor gene and has been found to have mutations in most human cancers. Mutations of p53 gene in human meningiomas have been reported in 7-13% of these tumors. According to the report of Pykett et al., however, there was lack of elevated p53 protein levels in 16 primary meningiomas. There were few reports about LOH at 17p. Kim et al. reported that LOH at 17p was identified in only two anaplastic meningiomas. In our study, LOH at 17p was seen with very low frequency in benign meningiomas (4%) and 80% of anaplastic meningiomas showed LOH. Also, there was a significant association between LOH at 17p and the grade of the tumor (p = 0.0006). Although we do not have data about the frequency of p53 gene somatic mutation, the findings of our study suggest that LOH at 17p might be associated with tumor progression in human meningiomas.

The hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic protein secreted by mesenchymatous cells, which has been identified as a potent mitogen for hepatocytes. The c-Met gene has been identified as a proto-oncogene in human osteogenic sarcoma and serves as a receptor for HGF/SF. HGF/SF and c-MET are located on chromosome 7q1. HGF and c-MET are associated with oncogenesis in many human cancers and co-expressed in meningiomas. A relationship between co-expression of HGF/c-MET and recurrence in meningiomas has been reported. Accordingly, the authors wanted to identify whether or not LOH at 7q is related to meningioma recurrence. However, LOH at 7q21 and 7q31 was seen at very low frequencies in our study (2.5% and 5%, respectively).

CONCLUSION

This study suggests LOH at 22q13 may contribute to meningeal tumorigenesis and LOH at 1p32 and 17p13 may be associated with tumor progression. However, LOH at 7q21 and 7q31 may not contribute to the development of meningiomas. Nevertheless, to determine the relationship between LOH at 7q and meningiomas, further studies are necessary.

References
1. Akagi K, Kuraishii H, Arita N, Hayakawa T, Monden M, Mori T, et al.: Deletion mapping of the long arm of chromosome 22 in human meningiomas. Int J Cancer 60: 178-182, 1995
2. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al.: Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94: 3210-3218, 2002
3. Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, et al.: Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ 3: 11-20, 1992
4. Bozetti C, Bortesi B, Meriesso C.: Loss of heterozygosity (LOH) in ovarian cancer. Int J Gynaecol Obstet 85: 294-295, 2004
5. Cooper CS, Park M, Blair DG, Talmny MA, Huebner K, Croce CM, et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33, 1984
6. Holstein M, Sidransky D, Vogelstein B, Harris CC.: p53 mutations in human cancers. Science 253: 69-53, 1991
7. Jeffers M, Rong S, Vande Woude GF.: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolytic network. Mol Cell Biol 16: 1115-1125, 1996
8. Karamitopoulou E, Perentes E, Diamantis I.: p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyclonal and DO-7 monoclonal antibodies. Acta Neuropathol (Berl) 85: 611-616, 1993
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
10. Kim JH, Lee SH, Rhee CH, Park SY, Lee JH.: Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. J Neurooncol 40: 101-106, 1999
11. Kleihues P, Louis DN, Scheithauer BW, Rutke LB, Reifenberger G, Burger PC, et al.: The WHO classification of tumours of the nervous system. J Neuropath Exp Neurol 61: 215-225; discussion 226-219, 2002
12. Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT Jr, Omalu B.: Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery 55: 1163-1173, 2004
13. Lee SH, Kim JH, Rhee CH, Kang YS, Lee JH, Choi KS.: Loss of heterozygosity on chromosome 10, 13, 17, and p53 gene mutation in human brain gliomas. J Korean Neurosurg Soc 22: 537-550, 1993
14. Leuraud P, Marie Y, Robin E, Huguet S, He J, Mokhtari K, et al.: Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas. J Neurooncol 50: 207-213, 2000
15. Liu Y.: The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 215: 159-169, 1998
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007
17. Martínez-Rumayor A, Arrieta O, Guevara P, Escolar E, Rembao D, Salina C, et al.: Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. *Cancer Lett* 213: 117-124, 2004

18. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K: Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. *Oncogene* 6: 1313-1318, 1991

19. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. *Cytokine Growth Factor Rev* 13: 41-59, 2002

20. Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S, Goya T, et al.: Comparative analysis of expression of hepatocyte growth factor and its receptor, c-Met, in gliomas, meningiomas and schwannomas in humans. *Cancer Lett* 124: 149-155, 1998

21. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel WI, Zang KD: Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. *J Neuropathol Exp Neurol* 56: 879-886, 1997

22. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al.: Mutations in the p53 gene occur in diverse human tumour types. *Nature* 342: 705-708, 1989

23. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P: p53 mutations in nonastrocytic human brain tumors. *Cancer Res* 51: 6202-6205, 1991

24. Park M, Dean M, Cooper CS, Schmidt M, O’Brien SJ, Blair DG, et al.: Mechanism of met oncogene activation. *Cell* 45: 895-904, 1986

25. Patil SR, Merrick S, Lubs HA: Identification of each human chromosome with a modified Giemsa stain. *Science* 173: 821-822, 1971

26. Pykett MJ, Landers J, George DL: Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas. *J Neurooncol* 32: 39-44, 1997

27. Riemschneider MJ, Perry A, Reifenberger G: Histological classification and molecular genetics of meningiomas. *Lancet Neurol* 5: 1045-1054, 2006

28. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al.: Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. *Cancer Res* 55: 4696-4701, 1995

29. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, et al.: Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. *Cancer Res* 58: 3226-3230, 1998

30. Ueki K, Wern-Bin C, Narita Y, Asai A, Kirino T: Tight association of loss of Merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. *Cancer Res* 59: 3226-3230, 1999

31. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al.: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. *Proc Natl Acad Sci U S A* 94: 14719-14724, 1997

32. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, et al.: A second-generation linkage map of the human genome. *Nature* 359: 794-801, 1992

33. Zankl H, Zang KD: Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. *Humangenetik* 14: 167-169, 1972

34. Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH: Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. *World J Gastroenterol* 10: 1431-1435, 2004